Andrew McPherson

Assistant Attending

Share
Print
Share
Print
Andrew McPherson

Office Phone

646-608-7558

Andrew McPherson is an Assistant Laboratory Member at the Memorial Sloan Kettering Cancer Center in the Department of Epidemiology and Biostatistics under the supervision of Dr. Sohrab Shah. Andrew completed a PhD in computing science at Simon Fraser University under the supervision of Dr. Cenk Sahinalp and Dr. Sohrab Shah, focusing on methods for sequencing analysis, including detection and characterization of genome rearrangements, and inference of clonal phylogenies. During his post-doctoral research at University of British Columbia with Dr. Sohrab Shah, Andrew focused on the development of computational methods and infrastructure for a novel single cell sequencing plaform, Direct Library Preparation. Andrew moved to MSKCC in May of 2019 and plans to build on his post-doctoral work in single cell genomics to understand genomic instability, mutational processes, clonal evolution and the role of the microenvironment in cancer development and progression.

Andrew has expertise in combinatorial optimization, machine learning and probabilistic modeling. He is interested in studying cancer biology problems that are combinatorially difficult to model, including phylogenetic inference, genome rearrangements, and clonal mixture decomposition. He focuses on problems relevant to cancer genomics; specifically chromosomal instability and its reshaping of chromosomes, mutational processes and the signatures they imprint on the genome, and interaction between tumour cells and the tumour microenvironment. In addition, he has an interest in big data software engineering and the development of optimal scientific discovery informatic workflows and processes.

Publications

  1. Zhang AW, McPherson A, et al. Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. Cell. 2018 Jun 14;173(7):1755-1769.e22. doi: 10.1016/j.cell.2018.03.073. Epub 2018 May 10. PubMed PMID: 29754820.
  2. McPherson AW, et al. ReMixT: clone-specific genomic structure estimation in cancer. Genome Biol. 2017 Jul 27;18(1):140. doi: 10.1186/s13059-017-1267-2. Erratum in: Genome Biol. 2017 Oct 6;18(1):188. PubMed PMID: 28750660; PubMed Central PMCID: PMC5530528.
  3. McPherson A, et al. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat Genet. 2016 Jul;48(7):758-67. doi: 10.1038/ng.3573. Epub 2016 May 16. PubMed PMID: 27182968.

To view more publications, visit PubMed

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Andrew McPherson discloses the following relationships and financial interests:

No disclosures meeting criteria for time period


The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures